Back to All Combinations

WRN Deficient (MSI-H)

Good Prognosis
3.00% Prevalence Level 3 Emerging Targets
Genes Involved
WRN
Treatment Implications

WRN helicase essential in MSI-H. Synthetic lethal approach.

Recommended Treatments
Treatments to Avoid

No specific contraindications noted

Study References

Chan et al Nature

Key Statistics
3.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Multiple WRN inhibitors in early trials.
Information

Category: Emerging Targets

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.